Spear Bio
PrivateLast Round
Series A
Jul 29, 2024
Total Funding Raised
$45M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Spear Bio operates in Healthcare & Life Sciences and is based in Woburn, Massachusetts. Its latest recorded funding round was a Series A round in July 2024.
Spear Bio is a biotechnology company that develops ultrasensitive immunoassay technology for protein biomarker detection in research and clinical diagnostics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spear Bio Comparables
Compare Spear Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Panacea Diagnostics | 78% | |
| Alamar Biosciences | 76% | |
| Quantum Diamond Technologies Inc. | 76% |
For institutional investors. Book with your work email.
Spear Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 29, 2024 | ||||
| Seed | Nov 29, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Spear Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Series A, Seed |
| Maverick Ventures | Seed, Series A |
| Yonjin Capital | Series A |
| Yonghua Capital | Seed |
| Foresite Capital | Series A |
| CDH Investments | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 46% MoM, from 4.1K to 6K.
- Jun 30, 2026
Commercial SPEAR S.W.I.F.T. instrument platform now being installed at customer sites.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardAug 11, 2026
Spear Bio Inc.'s SPEAR UltraDetect(TM) BD-pTau 217 Assay receives the 2026 R&D 100 Award from R&D World in Massachusetts on Aug 11th '26 for its innovation in ultrasensitive measurement of brain-derived pTau 217 in plasma.
For institutional investors. Book with your work email.
Spear Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Spear Bio's valuation, stock price, and market status.
Is Spear Bio a public or private company?
Spear Bio is a private company.
What is the current stock price of Spear Bio?
Spear Bio is a private company, so its shares have no public market price. Caplight tracks Spear Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Spear Bio worth (valuation)?
Valuation information for Spear Bio is not publicly available.
Can I buy Spear Bio stock?
Spear Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Spear Bio's last funding round?
Spear Bio's most recent funding round was Series A on July 29, 2024.
Who are the main investors in Spear Bio?
Key investors in Spear Bio include CDH Investments, Foresite Capital, CDH Investments.
Will Spear Bio IPO soon?
No public IPO plans have been announced for Spear Bio.
How can I track Spear Bio secondary market activity?
Caplight tracks bids, offers, and trades in Spear Bio's shares on secondary markets.